Non-exclusive discount agreements for medicines containing betahistine

Summary

The tender concerns non-exclusive medicine discount agreements for medicinal products containing the active ingredient betahistine (ATC N07CA01), excluding the 6 mg and 12 mg strengths. DAK-Gesundheit intends to conclude discount agreements with as many interested pharmaceutical companies as possible under the relevant German statutory framework. The agreements are planned for 1 October 2026 to 30 September 2028, with a one-time 12-month extension option, and will end automatically when an exclusive agreement enters into force. Precise exclusion, qualification and compliance requirements must be checked in the official tender documents.